Cardiovascular Drugs Practice Questions

Q: In a patient taking amiodarone, which factor most contributes to its potential to cause thyroid dysfunction?

High iodine content of amiodarone. ***High iodine content of amiodarone*** - Amiodarone contains approximately **37% iodine by weight**, leading to a significant daily iodine load that can disrupt normal thyroid function. - This excessive iodine can induce both **hypothyroidism (Wolff-Chaikoff effect)** and **hyperthyroidism (Jod-Basedow effect)** in susceptible individuals. *Direct thyroid toxicity* - While amiodarone can cause direct cytotoxic effects on thyroid cells, this is a **less prominent mechanism** compared to its iodine content in causing dysfunction. - **Amiodarone-induced destructive thyroiditis** (Type 2 AIT) involves direct thyroid damage and release of preformed hormones, but the initial trigger for widespread dysfunction is often the iodine. *Inhibition of TSH secretion* - Amiodarone does not primarily inhibit **TSH secretion**; in fact, TSH levels may be altered as a *result* of amiodarone's effects on thyroid hormone synthesis or release. - **Hypothyroidism** caused by amiodarone is typically characterized by **elevated TSH** due to reduced thyroid hormone production. *Inhibition of peripheral T4 to T3 conversion* - Amiodarone does inhibit the **peripheral conversion of T4 to T3** by blocking the 5'-deiodinase enzyme. - While this contributes to changes in thyroid hormone levels (e.g., elevated T4, reduced T3), it is **not the primary factor** responsible for the wide range of amiodarone-induced thyroid dysfunctions (hyper- and hypothyroidism), which are more directly linked to its high iodine load.

Q: Which of the following pharmacological agents can be used to induce stress during myocardial radionucleotide perfusion imaging?

All of the options. ***All of the options*** - **Dipyridamole**, **adenosine**, and **dobutamine** are all pharmacological agents commonly used to induce stress for myocardial perfusion imaging. - They produce coronary vasodilation (dipyridamole, adenosine) or increased myocardial oxygen demand (dobutamine) to unmask **ischemia**. *Dipyridamole* - **Dipyridamole** inhibits adenosine reuptake and phosphodiesterase, leading to increased extracellular adenosine, causing **coronary vasodilation**. - Its use can result in a steal phenomenon where blood is diverted from stenosed areas to healthy vessels. *Adenosine* - **Adenosine** is a direct vasodilator of coronary arteries, creating a disparity in blood flow between normal and stenotic vessels. - It has a very short half-life (~10 seconds), allowing for rapid onset and offset of its effects. *Dobutamine* - **Dobutamine** is a beta-1 adrenergic agonist that increases heart rate and myocardial contractility, thereby increasing myocardial oxygen demand. - It is often used as a stress agent when patients have contraindications to vasodilators.

Q: Which of the following is NOT a side effect of amiodarone?

Tachycardia. ***Tachycardia*** - **Amiodarone** is an antiarrhythmic drug primarily used to treat and prevent **tachyarrhythmias**, meaning it generally slows down heart rate and is not associated with causing tachycardia. - Its main effect is to prolong the **refractory period** in myocardial cells, which helps to stabilize abnormal heart rhythms, rather than inducing them. *Pulmonary fibrosis* - **Amiodarone** is well-known for its potential to cause **pulmonary toxicity**, including **interstitial lung disease** and **pulmonary fibrosis**, which can be severe and even fatal. - This side effect is thought to be dose-dependent and can manifest as shortness of breath and cough, requiring careful monitoring. *Corneal microdeposits* - **Corneal microdeposits**, often described as **whorl keratopathy** or **cornea verticillata**, are a very common and usually benign side effect of **amiodarone**. - These deposits typically do not affect vision but can cause blurred vision or halos around lights in some patients. *Photosensitivity* - **Photosensitivity** is a common dermatological side effect of **amiodarone**, leading to an exaggerated sunburn reaction or a grayish-blue skin discoloration in sun-exposed areas. - Patients are advised to use **sunscreen** and protective clothing while on **amiodarone** to minimize this risk.

Q: Which of the following antilipidemic drugs is a sterol absorption inhibitor?

Ezetimibe. ***Ezetimibe*** - **Ezetimibe** acts by inhibiting the **Niemann-Pick C1-like 1 (NPC1L1) protein**, which is responsible for the absorption of cholesterol and phytosterols in the small intestine. - This mechanism directly reduces the amount of dietary and biliary cholesterol absorbed, leading to a decrease in **LDL-C** levels. *Gemfibrozil* - **Gemfibrozil** is a **fibrate**, primarily acting as a **PPAR-α agonist** to increase lipoprotein lipase activity. - Its main effects are reducing **triglycerides** and increasing **HDL-C**, not directly inhibiting sterol absorption. *Simvastatin* - **Simvastatin** is an **HMG-CoA reductase inhibitor** (statin), which reduces cholesterol synthesis in the liver. - It works by blocking the rate-limiting step in cholesterol biosynthesis, not by inhibiting sterol absorption from the gut. *Nicotinic acid* - **Nicotinic acid** (niacin) primarily works by inhibiting **hepatic VLDL secretion** and decreasing the catabolism of HDL. - Its main effects are increasing **HDL-C** and lowering **triglycerides** and **LDL-C**, through a mechanism distinct from sterol absorption inhibition.

Q: What is the mechanism of action of Iloprost?

PGI 2 analogue. ***Thromboxane receptor antagonist*** - This statement is incorrect. **Iloprost** is an analogue of **prostacyclin (PGI2)**, not a thromboxane receptor antagonist. - It works by mimicking the effects of natural prostacyclin, leading to **vasodilation** and **inhibition of platelet aggregation**. *Thromboxane synthetase antagonist* - **Thromboxane synthetase inhibitors** prevent the production of thromboxane A2, a potent vasoconstrictor and platelet aggregator. - While this is a different mechanism from iloprost, drugs like **dazoxiben** act this way to achieve similar clinical effects of reduced vasoconstriction and platelet aggregation. *PGE 1 analogue* - **PGE1 analogues** (like **alprostadil**) are primarily used to maintain patent ductus arteriosus in neonates or for erectile dysfunction. - While PGE1 also has vasodilatory and antiplatelet effects, **iloprost** specifically mimics **PGI2**. *PGI 2 analogue* - This is the **correct mechanism of action** for **Iloprost**. Iloprost is a stable synthetic analogue of **prostacyclin (PGI2)**. - By activating **prostacyclin receptors**, it causes **vasodilation** (especially in the pulmonary and systemic vasculature) and potent **inhibition of platelet aggregation**.

Q: Mechanism of action of Torcetrapib is ?

CETP inhibitors. ***CETP inhibitors*** - **Torcetrapib** is a **cholesteryl ester transfer protein (CETP) inhibitor** designed to increase HDL cholesterol levels by preventing the transfer of cholesteryl esters from HDL to VLDL and LDL. - Despite its mechanism aiming to raise HDL, **Torcetrapib** significantly **failed in clinical trials** due to an unexpected increase in cardiovascular events and mortality, possibly linked to off-target effects like elevated blood pressure. *Bile acid sequestrant* - **Bile acid sequestrants** (e.g., cholestyramine) work by binding to **bile acids in the intestine**, preventing their reabsorption and increasing their fecal excretion. - This leads to an **upregulation of hepatic LDL receptors** to synthesize new bile acids from cholesterol, thereby lowering plasma LDL levels. *Sterol absorption inhibitor* - **Sterol absorption inhibitors** (e.g., ezetimibe) act by **blocking the Niemann-Pick C1-like 1 (NPC1L1) protein** in the small intestine. - This mechanism specifically **reduces the absorption of dietary and biliary cholesterol**, leading to decreased delivery of cholesterol to the liver and subsequent lowering of LDL-C. *Lipoprotein lipase activator* - A **lipoprotein lipase (LPL) activator** would increase the activity of LPL, an enzyme that **hydrolyzes triglycerides** in chylomicrons and VLDL. - This action would primarily lead to a **reduction in triglyceride-rich lipoproteins** and an increase in HDL, but **Torcetrapib** does not function through LPL activation.

Q: Which of the following antiarrhythmic drugs can cause Long QT syndrome?

All of the options. ***All of the options*** - **Dofetilide**, **sotalol**, and **ibutilide** are all Class III antiarrhythmic agents that primarily block potassium channels, thereby prolonging the **repolarization phase** of the action potential. - This prolongation of repolarization can increase the duration of the **QT interval** on an electrocardiogram, predisposing patients to **Torsades de Pointes**, a life-threatening polymorphic ventricular tachycardia. *Dofetilide* - **Dofetilide** is a selective **potassium channel blocker** (Class III antiarrhythmic) known to prolong the QT interval in a dose-dependent manner. - Its use requires careful monitoring of the QT interval due to the significant risk of inducing **Torsades de Pointes**. *Sotalol* - **Sotalol** has both **beta-blocking** (Class II) and **potassium channel blocking** (Class III) properties. - Its Class III activity, specifically the blockade of the **delayed rectifier potassium current**, leads to QT prolongation and the risk of proarrhythmia. *Ibutilide* - **Ibutilide** is a Class III antiarrhythmic that acts primarily by activating a **slow inward sodium current** and blocking the rapid component of the delayed rectifier potassium current (IKr). - This dual action strongly prolongs the action potential duration and effective refractory period, resulting in a significant risk of **QT prolongation** and **Torsades de Pointes**, especially when converted from atrial rhythm.

Q: Which of the following statements about the mechanism of action of digitalis is incorrect?

Digitalis action is independent of cardiac innervation. ***Digitalis action is independent of cardiac innervation*** - This statement is **incorrect** because digitalis, while directly affecting cardiac contractility, also has **indirect effects** through the **vagus nerve**, leading to decreased heart rate and atrioventricular conduction. - Its effects can be modulated by the **autonomic nervous system**, indicating it is not entirely independent of cardiac innervation. *There is rise in intracellular Na+* - Digitalis **inhibits the Na+/K+-ATPase pump**, leading to an **accumulation of intracellular sodium (Na+)**. - This increased intracellular Na+ then reduces the activity of the **Na+/Ca2+ exchanger**, causing a rise in intracellular **calcium (Ca2+)** levels. *It has positive inotropic action* - The increased intracellular Ca2+ due to Na+/K+-ATPase pump inhibition leads to more Ca2+ being released from the sarcoplasmic reticulum, enhancing the interaction between actin and myosin. - This results in increased force of myocardial contraction, which is known as a **positive inotropic effect**. *It binds to the extracellular face of Na+ ATPase enzyme* - Digitalis **binds to a specific receptor site on the extracellular face** of the alpha subunit of the **Na+/K+-ATPase enzyme**. - This binding leads to a conformational change that inhibits the pump's activity.

Q: What is the mechanism of action of nicorandil?

K+ channel opener. ***K+ channel opener*** - **Nicorandil** acts as a **potassium channel opener**, specifically targeting ATP-sensitive potassium channels (K-ATP channels) in vascular smooth muscle - Opening these channels leads to **hyperpolarization** of the cell membrane, causing relaxation of smooth muscle and **vasodilation** - Nicorandil also has a **nitrate-like effect**, providing a dual mechanism for its antianginal action - This mechanism makes it effective in **stable angina** and **coronary vasospasm** *K+ channel blocker* - Potassium channel blockers (e.g., certain antiarrhythmics like amiodarone) inhibit potassium efflux, leading to **prolonged repolarization** and increased action potential duration - This mechanism is opposite to nicorandil's action and is used for **antiarrhythmic purposes**, not for vasodilation - Would cause vasoconstriction rather than the vasodilation seen with nicorandil *Na+ channel blocker* - Sodium channel blockers (e.g., local anesthetics, Class I antiarrhythmics) inhibit sodium influx, thereby **stabilizing cell membranes** and reducing excitability - This mechanism does not explain the **vasodilation** characteristic of nicorandil - Primarily used for arrhythmias, local anesthesia, or neurological conditions *Cl- channel blocker* - Chloride channel blockers are not a primary mechanism for drugs producing **vasodilation** like nicorandil - Their effects are typically related to **fluid secretion** or **cell volume regulation** (e.g., in cystic fibrosis or secretory diarrhea) - This mechanism is distinct from nicorandil's cardiovascular actions

Q: What is the primary reason for the short half-life of adenosine in the bloodstream?

Rapid uptake by red blood cells and endothelial cells. ***Rapid uptake by red blood cells and endothelial cells*** - **Adenosine** is rapidly transported into cells, particularly **red blood cells** and **vascular endothelial cells**, via specific **nucleoside transporters**. - Once inside these cells, adenosine is quickly metabolized by **adenosine deaminase** into inosine or phosphorylated by **adenosine kinase** into AMP, limiting its systemic half-life to a few seconds. *Uptake in subcutaneous tissue of adenosine* - While some uptake might occur in various tissues, **subcutaneous tissue** is not the primary site responsible for the rapid clearance and extremely short half-life of adenosine in the bloodstream. - The rapid action and metabolism of adenosine primarily occur in the **vascular compartment** and circulating blood cells. *Renal excretion of adenosine* - **Renal excretion** plays a minor role in the elimination of intact adenosine from the bloodstream due to its rapid cellular uptake and metabolism. - The majority of adenosine is metabolized intracellularly before it can be filtered by the kidneys. *Spontaneous hydrolysis of adenosine* - **Spontaneous hydrolysis** is not a significant mechanism contributing to the rapid breakdown and short half-life of adenosine in the human body. - Enzymatic degradation by **adenosine deaminase** is the primary catabolic pathway.

Question 1

In a patient taking amiodarone, which factor most contributes to its potential to cause thyroid dysfunction?

Accepted Answer

High iodine content of amiodarone

Answer

Direct thyroid toxicity

Answer

Inhibition of TSH secretion

Answer

Inhibition of peripheral T4 to T3 conversion

Question 2

Which of the following pharmacological agents can be used to induce stress during myocardial radionucleotide perfusion imaging?

Accepted Answer

All of the options

Answer

Adenosine

Answer

Dobutamine

Answer

Dipyridamole

Question 3

Which of the following is NOT a side effect of amiodarone?

Accepted Answer

Tachycardia

Answer

Corneal microdeposits

Answer

Photosensitivity

Answer

Pulmonary fibrosis

Question 4

Which of the following antilipidemic drugs is a sterol absorption inhibitor?

Accepted Answer

Ezetimibe

Answer

Gemfibrozil

Answer

Simvastatin

Answer

Nicotinic acid

Question 5

What is the mechanism of action of Iloprost?

Accepted Answer

PGI 2 analogue

Answer

Thromboxane synthetase antagonist

Answer

Thromboxane receptor antagonist

Answer

PGE 1 analogue

Question 6

Mechanism of action of Torcetrapib is ?

Accepted Answer

CETP inhibitors

Answer

Bile acid sequestrant

Answer

Sterol absorption inhibitor

Answer

Lipoprotein lipase activator

Question 7

Which of the following antiarrhythmic drugs can cause Long QT syndrome?

Accepted Answer

All of the options

Answer

Dofetilide

Answer

Sotalol

Answer

Ibutilide

Question 8

Which of the following statements about the mechanism of action of digitalis is incorrect?

Accepted Answer

Digitalis action is independent of cardiac innervation

Answer

There is rise in intracellular Na+

Answer

It has positive inotropic action

Answer

It binds to the extracellular face of Na+ ATPase enzyme

Question 9

What is the mechanism of action of nicorandil?

Accepted Answer

K+ channel opener

Answer

Cl- channel blocker

Answer

K+ channel blocker

Answer

Na+ channel blocker

Question 10

What is the primary reason for the short half-life of adenosine in the bloodstream?

Accepted Answer

Rapid uptake by red blood cells and endothelial cells

Answer

Uptake in subcutaneous tissue of adenosine

Answer

Renal excretion of adenosine

Answer

Spontaneous hydrolysis of adenosine

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?